The Bahrain Oncology Centre (BOC) has reached a major milestone by offering CASGEVY gene therapy for sickle cell disease and transfusion dependent thalassemia, making it one of the first centers worldwide to provide this groundbreaking treatment. This achievement comes after the BOC received accreditation for its adherence to international standards for bone marrow transplant and cell therapy services.
The first Bahraini patient with sickle cell disease is set to undergo the CASGEVY treatment, ushering in a new era of advanced healthcare in the region. The launch of the CASGEVY program is a collaborative effort involving the Ministry of Health, the Royal Medical Services, Government Hospitals, and the National Health Regulatory Authority. This initiative aligns with the vision of His Majesty King Hamad bin Isa Al Khalifa to elevate Bahrain’s healthcare sector and provide high-quality care for all citizens, especially those with inherited blood disorders.
The BOC underwent a thorough evaluation process and on-site audit to become certified as a center for bone marrow transplant and cell therapy services. The center demonstrated its expertise, advanced equipment, and adherence to international standards for hematopoietic cell transplantation and cell therapy. The certification reinforces Bahrain’s position as a regional leader in healthcare innovation.
The CASGEVY therapy involves various stages, including patient assessment, blood exchange transfusion to prepare the bone marrow, stem cell collection, genetic editing in a laboratory, and rigorous quality checks to ensure the safety and effectiveness of the modified cells. After transplantation, the patient is closely monitored as the new cells begin producing healthy red blood cells in the bone marrow.
By partnering with national institutions, the Bahrain Oncology Centre is dedicated to advancing healthcare and providing access to state-of-the-art medical technologies for the entire community. The recent accreditation further establishes Bahrain as a leader in innovative healthcare solutions. With a commitment to excellence and collaboration, the BOC is paving the way for improved outcomes and increased access to cutting-edge treatments for patients with blood disorders.
